Drug intelligence / Profile preview

igermetostat + abiraterone + prednisone

Development stage: Unknown
Lead developer: Evopoint Biosciences
Modality: Small Molecules
Administration: Oral

Overview

XNW5004 + abiraterone + prednisone is an investigational combination regimen consisting of the oral small molecule EZH2 inhibitor igermetostat (XNW5004), the CYP17A1 inhibitor abiraterone, and the corticosteroid prednisone. Igermetostat targets Enhancer of Zeste Homolog 2 (EZH2), an epigenetic regulator whose overexpression is linked to poor prognosis and treatment resistance in metastatic castration-resistant prostate cancer (mCRPC). Abiraterone blocks androgen biosynthesis by inhibiting the CYP17 enzyme complex, while prednisone is co-administered to manage mineralocorticoid excess associated with abiraterone treatment. Developed by Evopoint Biosciences, this combination is being evaluated in Phase Ib/II clinical trials for its potential to overcome resistance to androgen receptor pathway inhibitors in patients with advanced prostate cancer.

Other names: igermetostat + abiraterone + prednisone

Targets

GR (Glucocorticoid receptor)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)

Beyond the preview

Go deeper on igermetostat + abiraterone + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on igermetostat + abiraterone + prednisone.

Explore the full profile